New Pyridone-Based Derivatives as Cannabinoid Receptor Type 2 Agonists

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Neuroscience

Background:

• Cannabinoid receptor type II (CB2R) activation offers therapeutic potential for pain and inflammation without the central side effects of CB1R.
• Developing selective CB2R agonists is a key goal in pharmaceutical research.

Purpose of the Study:

• To synthesize and evaluate a novel series of N-aryl-2-pyridone-3-carboxamide derivatives as CB2R agonists.
• To identify potent and non-toxic CB2R-activating small molecules for therapeutic development.

Main Methods:

• Synthesis of N-aryl-2-pyridone-3-carboxamide derivatives.
• In vitro evaluation of CB2R agonist activity using intracellular cAMP levels.
• Molecular docking studies to elucidate binding modes and structural requirements.

Main Results:

• Several derivatives demonstrated CB2R agonist activity.
• Compound 8d showed potent (EC50 = 112 nM) and non-toxic CB2R activation, comparable to endogenous agonists.
• Molecular docking revealed binding poses consistent with known CB2R agonists, suggesting key structural features for activity.

Conclusions:

• The 2-pyridone scaffold is a viable platform for designing effective CB2R agonists.
• Compound 8d represents a promising lead for developing novel therapeutics for pain and inflammation.